Adam H. Schechter
Known title: DirectorCIK: 0001376841
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Labcorp to Acquire OPKO Health's BioReference Assets for $722M. Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.
Transaction History
| DVA | ▲ Buy | Grant | 278 | $0 | 8/15/2026 | View on chart |
| LH | ▼ Sell | Open Market | 4,669 | $1.5M | 8/11/2026 | View on chart |
| DVA | ▲ Buy | Grant | 250 | $0 | 5/15/2026 | View on chart |
| LH | ▼ Sell | Open Market | 5,903 | $1.5M | 5/11/2026 | View on chart |
| LH | ▼ Sell | Tax Withholding | 26,106 | $7.0M | 3/26/2026 | View on chart |
| LH | ▲ Buy | Grant | 58,470 | $0 | 3/26/2026 | View on chart |
| DVA | ▲ Buy | Grant | 332 | $0 | 3/15/2026 | View on chart |
| LH | ▼ Sell | Open Market | 8,705 | $2.4M | 3/3/2026 | View on chart |
| LH | ▼ Sell | Open Market | 5,273 | $1.5M | 2/11/2026 | View on chart |
| LH | ▲ Buy | Option Exercise | 3,656 | — | 2/11/2026 | View on chart |
| LH | ▼ Sell | Tax Withholding | 1,521 | $441K | 2/11/2026 | View on chart |
| LH | ▼ Sell | Tax Withholding | 1,352 | $370K | 2/9/2026 | View on chart |
| LH | ▲ Buy | Option Exercise | 3,249 | — | 2/7/2026 | View on chart |
| LH | ▼ Sell | Tax Withholding | 1,315 | $365K | 2/6/2026 | View on chart |
| LH | ▲ Buy | Option Exercise | 4,460 | — | 2/6/2026 | View on chart |
| DVA | ▲ Buy | Grant | 411 | $0 | 11/15/2025 | View on chart |
| LH | ▼ Sell | Open Market | 5,745 | $1.5M | 11/11/2025 | View on chart |
| DVA | ▲ Buy | Grant | 369 | $0 | 8/15/2025 | View on chart |
| LH | ▼ Sell | Open Market | 5,643 | $1.5M | 8/11/2025 | View on chart |
| DVA | ▲ Buy | Grant | 348 | $0 | 5/15/2025 | View on chart |
| LH | ▼ Sell | Open Market | 6,105 | $1.5M | 5/12/2025 | View on chart |
| LH | ▲ Buy | Grant | 30,469 | $0 | 3/27/2025 | View on chart |
| LH | ▼ Sell | Tax Withholding | 13,584 | $3.1M | 3/27/2025 | View on chart |
| DVA | ▲ Buy | Grant | 349 | $0 | 3/15/2025 | View on chart |
| LH | ▼ Sell | Tax Withholding | 1,226 | $301K | 2/11/2025 | View on chart |
| LH | ▲ Buy | Option Exercise | 2,963 | — | 2/11/2025 | View on chart |
| LH | ▼ Sell | Open Market | 6,121 | $1.5M | 2/11/2025 | View on chart |
| LH | ▼ Sell | Tax Withholding | 1,345 | $331K | 2/7/2025 | View on chart |
| LH | ▲ Buy | Option Exercise | 3,250 | — | 2/7/2025 | View on chart |
| LH | ▲ Buy | Option Exercise | 4,460 | — | 2/6/2025 | View on chart |
| LH | ▼ Sell | Tax Withholding | 1,240 | $307K | 2/6/2025 | View on chart |
| DVA | ▲ Buy | Grant | 312 | $0 | 11/15/2024 | View on chart |
| LH | ▼ Sell | Open Market | 6,189 | $1.5M | 11/11/2024 | View on chart |
| DVA | ▲ Buy | Grant | 333 | $0 | 8/15/2024 | View on chart |
| DVA | ▲ Buy | Grant | 363 | $0 | 5/15/2024 | View on chart |
| LH | ▼ Sell | Tax Withholding | 31,799 | $6.9M | 3/27/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 72,435 | — | 3/27/2024 | View on chart |
| DVA | ▲ Buy | Grant | 366 | $0 | 3/15/2024 | View on chart |
| LH | ▼ Sell | Tax Withholding | 1,231 | $280K | 2/12/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 2,964 | — | 2/11/2024 | View on chart |
| LH | ▼ Sell | Tax Withholding | 1,149 | $257K | 2/7/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 3,250 | — | 2/7/2024 | View on chart |
| LH | ▼ Sell | Tax Withholding | 822 | $182K | 2/2/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 3,094 | — | 2/2/2024 | View on chart |
| DVA | ▲ Buy | Grant | 529 | $0 | 11/15/2023 | View on chart |
| DVA | ▲ Buy | Grant | 475 | $0 | 8/15/2023 | View on chart |
| DVA | ▲ Buy | Grant | 516 | $0 | 5/15/2023 | View on chart |
| LH | ▼ Sell | Tax Withholding | 18,646 | $4.2M | 3/30/2023 | View on chart |
| LH | ▲ Buy | Grant | 42,353 | $0 | 3/30/2023 | View on chart |
| DVA | ▲ Buy | Grant | 658 | $0 | 3/15/2023 | View on chart |
| LH | ▼ Sell | Tax Withholding | 1,170 | $290K | 2/13/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 2,656 | — | 2/11/2023 | View on chart |
| LH | ▼ Sell | Tax Withholding | 1,368 | $334K | 2/6/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 3,507 | — | 2/4/2023 | View on chart |
| LH | ▼ Sell | Tax Withholding | 805 | $205K | 2/2/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 2,773 | — | 2/2/2023 | View on chart |
| DVA | ▲ Buy | Grant | 81 | $0 | 11/15/2022 | View on chart |
| LH | ▼ Sell | Tax Withholding | 893 | $199K | 11/1/2022 | View on chart |
| LH | ▲ Buy | Option Exercise | 2,007 | — | 11/1/2022 | View on chart |
| LH | ▼ Sell | Tax Withholding | 1,412 | $392K | 2/4/2022 | View on chart |
| LH | ▲ Buy | Option Exercise | 3,507 | — | 2/4/2022 | View on chart |
| LH | ▲ Buy | Option Exercise | 2,773 | — | 2/2/2022 | View on chart |
| LH | ▼ Sell | Tax Withholding | 803 | $219K | 2/2/2022 | View on chart |
| LH | ▲ Buy | Option Exercise | 2,007 | — | 11/1/2021 | View on chart |
| LH | ▼ Sell | Tax Withholding | 886 | $256K | 11/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
DaVita (DVA) Discussed as Potentially Undervalued Cash Producer
Recent articles highlight DaVita as a cash-producing stock that may be undervalued relative to its earnings power. The company has outperformed the broader market recently, with one analysis noting a 58% gain. While the stock is trading near its 52-week low, analysts maintain a higher average price target, suggesting a gap between current price and long-term expectations.
DaVita (DVA) Discussed as Potentially Undervalued Cash Producer. Recent articles highlight DaVita as a cash-producing stock that may be undervalued relative to its earnings power. The company has outperformed the broader market recently, with one analysis noting a 58% gain. While the stock is trading near its 52-week low, analysts maintain a higher average price target, suggesting a gap between current price and long-term expectations.